KIRKLAND, Wash.--(BUSINESS WIRE)--Prevencio, Inc. today announces a new research collaboration with Seattle Children’s Research Institute leveraging Prevencio’s AI expertise in developing highly accurate blood tests. Seattle Children’s is dedicated to making breakthrough discoveries for childhood diseases and sought to partner with Prevencio to develop a test for Kawasaki Disease, a rare but fatal childhood disease, which can be triggered by COVID-19. Seattle Children’s will provide blood samples to Prevencio who will use its proven HART AI platform to develop a blood test. Prevencio retains exclusive world-wide rights. Additional terms of the deal are not disclosed.
Michael Portman, MD, director of pediatric cardiovascular research at Seattle Children’s and professor of pediatrics at the University of Washington School of Medicine, stated, “Kawasaki disease occurs mostly in children younger than 5 years old. Among the main presenting symptoms are persistent fever and rash. This makes diagnosis challenging as so many children with these symptoms present to U.S. emergency rooms. With COVID-19, diagnosis for Kawasaki disease has become even more challenging and critical as the two have similar presenting symptoms, and it appears that Kawasaki Disease can be triggered by the COVID virus.”
Portman added, “Without early treatment, there is a 25-30% risk of heart artery lesions which can lead to ballooning, also called aneurysms, of the heart vessels. To date, there is no diagnostic test for Kawasaki disease, and we are excited to partner with Prevencio to address this critical, unmet medical need.”
Prevencio will use their long-standing, certified laboratory partner, Myriad RBM, to conduct protein measurements on the blood of children with Kawasaki disease.
“We are pleased to collaborate with Seattle Children’s Research Institute, one of the nation’s top five pediatric research centers,” stated Rhonda Rhyne, Prevencio’s Chief Executive Officer. “We have robust experience developing highly accurate blood tests for heart disease and related complications. We are very pleased to expand use of our AI Hart platform for Kawasaki Disease and to be a part of addressing COVID-related medical issues.”
About Prevencio HART Tests:
Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Employing this novel approach, the company has developed seven blood tests that significantly improve diagnoses for a variety of heart and blood vessel-related complications.
- HART CADTM / CADhsTM – obstructive coronary artery disease diagnosis
- HART CVETM – 1-year risk of heart attack, stroke or cardiac death
- HART PADTM – peripheral artery disease diagnosis
- HART ASTM – aortic valve stenosis diagnosis
- HART AMPTM – amputation risk
HART AKITM – acute kidney injury risk
HART test results have been presented at leading cardiovascular meetings—(European Society of Cardiology Congress – 2016, 2018, American College of Cardiology Scientific Sessions – 2017, 2018, 2019, 2020, American Heart Association Scientific Sessions – 2017, 2018, 2019, and American Diabetes Association Scientific Sessions – 2018, 2019) and published in top-tier journals—(Journal of American College of Cardiology – Mar 2017, American Journal of Cardiology – July 2017, Open Heart – November 2018 and Clinical Cardiology – June 2018, Jan 2019).
About Prevencio, Inc.:
Prevencio's value proposition is "Preventing the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for Cardiovascular Disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests. The company is headquartered in Kirkland, Washington. For additional information, visit www.PrevencioMed.com.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to uncertainties and risks including the Company’s sole dependence on HART technology and various uncertainties of development-stage companies. The Company does not undertake to update disclosures contained in this press release.